All In MedTech

FDA Clearance Tracker · K252336

Diazyme Immunoglobulin A Assay; Diazyme Immunoglobulin G Assay; Diazyme Immunoglobulin M Assay

A 510(k) clearance means FDA found the device substantially equivalent to one already on the market. It is not an approval, and it is not a finding that the device works better than others.

Last checked: Nov 20, 2026Latest source record: Apr 24, 2026 (this decision)Source: openFDAMethods & limitations

510(k)

Decided

Apr 24, 2026

Substantially Equivalent

Time to decision

270 days

Received Jul 28, 2025. Calendar days, including time FDA spent waiting on the applicant.

Pathway

510(k)

Traditional

Device class

Not stated

The decision

FDA number
K252336
Device name
Diazyme Immunoglobulin A Assay; Diazyme Immunoglobulin G Assay; Diazyme Immunoglobulin M Assay
Applicant location
Poway, CA
Received
Jul 28, 2025
Decided
Apr 24, 2026
Decision
Substantially Equivalent
Submission type
Traditional

Device type

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • We could not check whether this was the first decision under its product code.
  • It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.

Source documents

  • FDA database record for K252336
  • The applicant filed a statement instead of a public summary, or the summary is not at FDA's usual address. Check the FDA record.

The predicate devices this clearance relied on are named in the summary document. We do not extract them yet.

Other decisions for Diazyme Laboratories, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

5 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.